QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-beam-therapeutics-maintains-80-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 ...

 jim-cramer-sees-more-upside-for-shopify-likes-coreweaves-ai-moves

Jim Cramer recommends buying Affirm Holdings (AFRM) on CNBC's Mad Money Lightning Round. Analysts also support Beam Therape...

 my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

 hc-wainwright--co-reiterates-buy-on-beam-therapeutics-maintains-80-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 ...

 pfizers-investigational-drug-flunks-late-stage-for-sickle-cell-disease

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on ...

 barclays-maintains-equal-weight-on-beam-therapeutics-lowers-price-target-to-21

Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $2...

 beam-therapeutics-enters-agreement-to-acquire-early-stage-life-sciences-company-for-403128-upfront-shares-and-up-to-89m-in-milestone-payments

On July 1, 2025, Beam Therapeutics Inc. (the "Company") entered into an Agreement and Plan of Merger pursuant to which ...

 cathie-woods-ark-invest-continues-to-offload-coinbase-bets-big-on-sofi-technologies

Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox.

 eli-lillys-13-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a...

 the-fda-has-granted-orphan-drug-designation-to-beam-therapeutics-beam-101-an-investigational-genetically-modified-cell-therapy-for-sickle-cell-disease

Data from seven patients treated with BEAM-101 in the BEACON clinical trial were presented at the 66th American Society of Hema...

 beam-therapeutics-receives-fda-orphan-drug-designation-for-beam-302-a-base-editing-therapy-targeting-alpha-1-antitrypsin-deficiency

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, toda...

 beam-therapeutics-to-present-new-data-from-beam-101-program-ii-sickle-cell-disease-at-european-hematology-association-2025-congress

Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evalua...

 beam-therapeutics-announces-us-fda-regenerative-medicine-advanced-therapy-designation-has-been-granted-to-beam-302-for-the-treatment-of-alpha-1-antitrypsin-deficiency

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, toda...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION